SEC Form 4 · accession 0001209191-15-044516
Tvardi Therapeutics, Inc. · TVRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dean Slagel
Director
Period of report
May 15, 2015
Accepted (ET)
May 19, 2015 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | May 15, 2015 | S | 73,600 | $10.00 | D | 1,473,549 | I | By Esperante BV |
| Common StockF4,F3 | May 18, 2015 | S | 82,945 | $10.04 | D | 1,390,604 | I | By Esperante BV |
| Common StockF5,F3 | May 19, 2015 | S | 32,266 | $10.00 | D | 1,358,338 | I | By Esperante BV |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold by Esperante BV (See Footnote (3) herein).
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 - $10.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3These shares are owned by Esperante BV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV and, as such, holds voting and/or dispositive power of the shares held by Esperante BV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 - $10.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 - $10.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.